What does a low‑dose menopausal hormone therapy (MHT) regimen look like for a perimenopausal woman who is either not using hormonal contraception or is using combined oral contraceptive pills?

Low-Dose Menopausal Hormone Therapy for Perimenopausal Women

For perimenopausal women not on birth control, start with low-dose combined estrogen-progestogen therapy using oral estradiol 0.5-1 mg daily with micronized progesterone 100 mg daily (or MPA 2.5 mg daily), or transdermal estradiol 0.025-0.0375 mg patches with appropriate progestogen; for those already on combined oral contraceptives, continue the COC until age 50-52 if no contraindications exist, as it provides both contraception and symptom relief at higher but appropriate doses for this life stage. 1, 2, 3

For Women NOT on Birth Control

Estrogen Component (Low-Dose Options)

• Oral estradiol: 0.5-1 mg daily
• Transdermal estradiol patches: 0.025-0.0375 mg (applied twice weekly)
• Conjugated equine estrogens (CEE): 0.3-0.45 mg daily (though estradiol preferred)

The transdermal route may offer advantages for women with increased cardiovascular or thromboembolic risk, as it bypasses first-pass hepatic metabolism 2, 3.

Progestogen Component (for women with intact uterus)

Endometrial protection is mandatory. Low-dose options include:

• Micronized progesterone: 100 mg daily (continuous) or 200 mg for 10-12 days/month (cyclic)
• Medroxyprogesterone acetate (MPA): 2.5 mg daily (continuous) or 5 mg for 10-12 days/month (cyclic)
• Norethindrone acetate: 0.35 mg daily (continuous) or 5 mg for 10-12 days/month (cyclic)
• Drospirenone: 3 mg daily (continuous)
• Levonorgestrel: 0.075 mg daily (continuous) 2

Key consideration: Micronized progesterone may have fewer side effects (mood swings, bloating) compared to synthetic progestogens, making it preferable for many perimenopausal women experiencing mood symptoms 2.

Regimen Selection

• Continuous-combined: Daily estrogen + daily progestogen (preferred for late perimenopause/postmenopause to minimize bleeding)
• Cyclic: Daily estrogen + progestogen 10-14 days/month (may be better tolerated in early perimenopause when still having periods)

For Women Already on Combined Oral Contraceptives

Continue the COC through perimenopause until age 50-52 if no contraindications develop 4, 3. This approach provides:

• Effective contraception (still needed during perimenopause)
• Symptom control for hot flashes and mood changes
• Cycle regulation

COC Dosing in Perimenopause

Standard low-dose COCs contain:

• Ethinyl estradiol: 20-30 mcg
• Progestogen: Various options (desogestrel 150 mcg, norgestimate, drospirenone, etc.)

Important caveat: If perimenopausal symptoms break through during the hormone-free interval (days 22-28), consider adding 5-10 mcg ethinyl estradiol during those 5-7 days, which significantly improves vasomotor symptoms, mood, and sexual function compared to placebo 5.

When to Transition from COC to MHT

Around age 50-52, transition to standard low-dose MHT as described above. The COC provides higher hormone doses than needed purely for symptom management once contraception is no longer required 3.

Critical Safety Screening Before Initiation

Absolute contraindications (do not prescribe MHT/COC):

• Current/past breast cancer or estrogen-sensitive malignancy
• Unexplained vaginal bleeding
• Active/recent VTE, PE, stroke, TIA, MI
• Active liver disease
• Untreated endometrial hyperplasia 2

Exercise extreme caution (consider alternatives):

• Age >60 years or >10 years past menopause onset
• High cardiovascular risk (diabetes, hypertriglyceridemia, smoking, family history)
• High breast cancer risk
• Migraine with aura
• Active gallbladder disease 1, 2

Monitoring and Duration

Start with the lowest effective dose and reassess every 6-12 months. The goal is symptom control with minimal risk. For women initiating therapy before age 60 or within 10 years of menopause, the benefit-risk ratio is favorable 1, 3.

Common pitfall: Many clinicians hesitate to prescribe any MHT due to outdated interpretations of WHI data. The evidence clearly supports use in appropriately selected younger perimenopausal women (age <60, <10 years from menopause) for quality of life improvement 1, 3.

Duration should be individualized based on persistent symptoms, but routine discontinuation "just because" is not evidence-based if symptoms persist and no contraindications develop 3.